Arcoxia, 60mg 14 Tabs
![]() Click image to enlarge |
|
Description
Arcoxia Merck Submits New Drug Application for Arcoxia WHITEHOUSE STATION, N.J., Dec. 30, 2003 - Merck & Co., Inc. today announced it has submitted a New Drug Application for ARCOXIA (etoricoxib) to the U.S. Food and Drug Administration (FDA). The application was submitted today. Merck’s NDA seeks indications for ARCOXIA for the treatment of osteoarthritis, rheumatoid arthritis, chronic low back pain, acute pain, dysmenorrhea, acute gouty arthritis and ankylosing spondylitis. Within the next 60 days, the FDA will determine whether it will accept Merck’s application as submitted. ARCOXIA has been launched in 38 countries worldwide in Europe, Latin America and the Asia-Pacific region. About Merck Merck & Co., Inc. is a global research-driven pharmaceutical products company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures.
Reviews
Your Review: Note: HTML is not translated!
Rating: Bad Good
Enter the code in the box below:
Are you serious about your health?
- Save Money - SAVE an additional 5% off every item.
- Save Time - Simplify your life with one less thing to remember.
- Never Run Out - Easy and reliable way to receive your items when you choose.